OneSource Specialty Pharma and Formycon AG Announce Strategic Partnership for Biosimilar Manufacturing
Bengaluru, India, July 14, 2026 - OneSource Specialty Pharma Limited, a multi-modality specialty pharma CDMO, and Formycon AG, an independent biosimilar developer headquartered in Munich, have announced a strategic manufacturing partnership focused on biosimilars.Under the terms of this collaboration, OneSource will function as a strategic manufacturing partner for Formycon. The partnership involves providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from OneSource's state-of-the-art biologics facility located in Bangalore. This joint effort combines Formycon's biosimilar development expertise with OneSource's end-to-end biologics manufacturing proficiency to support Formycon’s global biosimilar programs.
The agreement underscores both companies' commitment to advancing the global availability of biosimilars by ensuring reliable, high-quality, and scalable manufacturing processes. OneSource is strategically positioned to deliver this through its specialized model.
Formycon possesses a robust pipeline and a strong track record in biosimilar development and commercialization. OneSource complements this with an integrated biologics platform that spans cell line development through commercial fill-finish, supported by five manufacturing facilities approved by leading global regulatory authorities including the US FDA and EMA. The company also maintains extensive expertise across sterile injectables, biologics, and drug-device combinations.
Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, stated, "We are delighted to partner with Formycon, one of the world's leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics."
Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, commented, "Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies."
Company Profiles and Capabilities
The partnership unites two specialized firms:| Company | Core Business Focus | Key Strengths |
|---|---|---|
| OneSource Specialty Pharma Limited | Global CDMO specializing in complex pharmaceutical products, including biologics, sterile injectables, and drug-device combinations. | Five state-of-the-art manufacturing facilities approved by US FDA and EMA; dedicated team of over 1,600 professionals. |
| Formycon AG | Independent developer of high-quality biosimilars across the entire value chain, from candidate selection to market delivery. | Three biosimilars already on the market (FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept); four pipeline candidates in development, including FYB206/pembrolizumab and FYB208/dupilumab. |
ONESOURCE Stock Price Movement
Shares of Onesource Specialty Pharma Limited are edging higher to ₹1688.7 as of 10:05 AM today, rising by 0.94% with a gain of ₹15.70. The stock maintains an active session, having moved between a low of ₹1659.4 and a high of ₹1693.9, supported by 43,387 shares traded so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.